FOLH1 and neoplasm: DOTA derivatives used as chelators of 225Ac and 225Ac-labeled probes with ABM targeting PSMA (SibuDAB, Fig. 17a) showed increased blood retention, high-tumor accumulation, and potent therapeutic efficacy in PSMA-expressing tumor-bearing mice [158].